Sanofi: FDA approves Sarclisa
(CercleFinance.com) - The Food and Drug Administration (FDA) of the United States has approved Sarclisa (isatuximab-irfc) in combination with Pomalidomide and dexamethasone (pom-dex) for the treatment of relapsed or refractory multiple myeloma (MMRR) in adults who have received at least two previous treatments - in particular lenalidomide and a protease inhibitor.
Sarclisa should soon be available to patients in the United States.
"Today's FDA approval of Sarclisa provides a new treatment option for patients with difficult-to-treat multiple myeloma. These are patients whose disease has returned or become resistant to their prior treatments," said Paul Hudson, Sanofi's CEO.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Sarclisa should soon be available to patients in the United States.
"Today's FDA approval of Sarclisa provides a new treatment option for patients with difficult-to-treat multiple myeloma. These are patients whose disease has returned or become resistant to their prior treatments," said Paul Hudson, Sanofi's CEO.
Copyright (c) 2020 CercleFinance.com. All rights reserved.